|Date: 2022/08/19 00:00:00|
|Type of bond||Structured bonds and notes|
|Issuer type||financial institution|
|Country of issue||DE|
|Coupon payment date||2024/10/11|
|Coupon payment period||at maturity|
|Investor tolerance||6 (scale 1-7)|
|Last trading day||2024/10/04|
|Advantages||Details you should be aware of|
What does the Prémiový dluhový cenný papír VACCINATION AUTOCALL offer?
PDCP VACCINATION AUTOCALL with the option of automatic early repayment provides the opportunity to gain an attractive annual yield of 8% (see Note). The total yield for its three-year duration can then reach up to 24%.
The payout of a yield and nominal value of PDCP VACCINATION AUTOCALL is derived from the price trend of the shares of three leading pharmaceutical companies, Pfizer, Moderna and Johnson & Johnson. General awareness of these companies has been raised in recent months as they were among the first in the world to place an effective COVID-19 vaccine on the market. This year it is expected that thanks to the successful vaccines, the revenues above all of Pfizer and Moderna will reach record levels. Analysts expect a gradual decrease in the revenues of these companies up to 2023 with increasing vaccine coverage rates and a decline in the pandemic.
The construction of PDCP VACCINATION AUTOCALL allows its automatic early repayment even in case of a slight decrease or stagnation of the underlying shares prices. PDCP VACCINATION AUTOCALL can be repaid early already after the first year or the following year depending on the fulfilment of the terms and conditions for early repayment.
How does Prémiový dluhový cenný papír VACCINATION AUTOCALL work?
For more information see the leaflet
Note 2: The initial value will be calculated by the provider based on the closing prices of the underlying assets on 4 October 2021.
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer